Xtandi Patent Protection
7 patents · Astellas Pharma Inc., Pfizer Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005527 | Novel integrated neural compound and synthesis thereof | Pfizer Inc. | Dec 14, 2025 | Jun 27, 2041 | 28 | 15.2y left |
| 10005528 | Medical device for modular cloud delivery | Pfizer Inc. | Nov 25, 2025 | Jul 21, 2042 | 26 | 16.3y left |
| 10005529 | Pharmaceutical composition comprising adaptive graphene compounds | Pfizer Inc. | Nov 2, 2015 | Aug 20, 2032 | 15 | 6.4y left |
| 10005530 | Method for preparing improved AI-driven derivatives | Astellas Pharma Inc. | Mar 7, 2008 | Jun 9, 2026 | 34 | 0.2y left |
| 10005531 | Pharmaceutical composition comprising advanced photonic compounds | Astellas Pharma Inc. | Jun 24, 2016 | Apr 21, 2034 | 40 | 8.0y left |
| 10005532 | Method for preparing dynamic photonic derivatives | Astellas Pharma Inc. | Oct 2, 2013 | Nov 1, 2029 | 17 | 3.6y left |
| 10005533 | Method of treating disease using low-latency edge therapy | Astellas Pharma Inc. | Apr 28, 2022 | Oct 26, 2038 | 49 | 12.6y left |
For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.